Healthcare Network and User Base - As of June 30, 2025, the platform has connected over 44,800 healthcare institutions, including more than 14,500 hospitals and over 30,300 grassroots healthcare institutions[10]. - The registered individual users on the platform reached 56.9 million, with an average of 3.3 million monthly active users in the six months ending June 30, 2025[10]. - The company collaborates with over 904,500 healthcare professionals, including approximately 46,700 registered doctors, to enrich its medical resources[10]. - The company has developed a digital healthcare service platform that integrates online and offline healthcare services, significantly expanding its service reach to over 260 cities nationwide[10]. - The company has established 11 regional operation centers in key areas such as Shenzhen, Beijing, Shanghai, and Guangzhou to enhance local service coverage[11]. Financial Performance - Total revenue for the six months ended June 30, 2025, was RMB 290.7 million, representing a year-on-year increase of 6.2%[16]. - Revenue from pharmaceutical health products sales reached RMB 211.4 million, up 7.4% year-on-year[19]. - The company reported an operating loss of RMB 18.0 million, a significant improvement of 77.8% compared to the previous year's loss of RMB 81.2 million[16]. - The adjusted net loss (non-IFRS measure) was RMB 5.1 million, a reduction of 83.7% from RMB 31.0 million in the prior year[16]. - Revenue from digital healthcare solutions was RMB 79.3 million, reflecting a year-on-year growth of 2.9%[20]. Cost Management and Expenses - Sales and marketing expenses decreased by 45.5% from approximately RMB 64.9 million to approximately RMB 35.4 million, primarily due to reduced employee benefits expenses and improved cost control measures[32]. - Administrative expenses fell by 46.5% from approximately RMB 51.5 million to approximately RMB 27.5 million, mainly due to a reduction in share-based payment expenses and travel costs[33]. - Research and development expenses decreased by 30.5% from approximately RMB 25.1 million to approximately RMB 17.5 million, reflecting a reduction in employee benefits expenses[35]. - The gross margin for pharmaceutical health products sales decreased from 1.9% to 1.3%, while the retail model's gross margin increased from 13.1% to 16.2% due to strategic adjustments in product selection and promotional activities[31]. Cash Flow and Liquidity - The operating cash flow for the six months ended June 30, 2025, was a net outflow of RMB 5.4 million, an improvement from a net outflow of RMB 40.7 million in the same period of 2024[44]. - The company reported a net cash inflow from financing activities of RMB 12.3 million for the six months ended June 30, 2025, compared to RMB 36.7 million in the same period of 2024[44]. - As of June 30, 2025, the company's cash and cash equivalents amounted to approximately RMB 66.8 million, an increase from RMB 58.3 million as of December 31, 2024[43]. - The company’s total liabilities exceeded current assets by RMB 107,091,000 as of June 30, 2025, highlighting potential liquidity challenges[111]. Shareholder and Equity Information - The total number of issued shares is 336,452,810[68]. - Major shareholders include Mr. Luo, holding approximately 30.59% of the company's shares[73]. - The company approved a pre-IPO share option plan on August 31, 2023, aimed at attracting and retaining senior management and employees[79]. - A total of 14,487,990 new shares and 16,696,595 existing shares can be issued under the pre-IPO share option plan, representing 4.31% and 4.96% of the total issued shares post-split and global offering, respectively[81]. - The company aims to align the interests of option holders with those of shareholders through the share option plan[79]. Future Plans and Investments - The company plans to adopt new accounting standards effective January 1, 2026, but does not expect significant impacts on its financial position or performance[113]. - The company plans to list its shares on the Hong Kong Stock Exchange on September 17, 2025[162]. - The company has no specific future plans for significant investments or capital assets as of June 30, 2025[50]. - The company continues to expand its market presence and promote its digital hospital solutions to enhance service levels and reach more regions[18]. Guarantees and Related Party Transactions - The company provided a revolving credit loan of RMB 60 million to its controlling shareholder, Mr. Luo, with an interest rate between 3.45% and 6%[151]. - The company has guaranteed loans totaling RMB 28,000,000 as of June 30, 2025, with various related parties providing collateral[152]. - The company has a loan guarantee of RMB 5,000,000 from Bank H, guaranteed by Mr. Luo, with a start date of January 13, 2025, and an end date of January 12, 2026[154].
健康１６０(02656) - 2025 - 中期财报